{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-033845","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2023-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.977650+00:00","generated_at":"2026-06-13T05:17:23.850624+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ARCA biopharma Q2 2023 net loss $1.5M; cash $40.2M; strategic review continues","bullets":["Net loss $1.5M ($0.10/sh) vs $3.1M ($0.22) in Q2 2022; total operating expenses $2.0M vs $3.2M.","Cash and equivalents $40.2M at June 30, 2023; expected to fund operations through end of 2024.","R&D expenses fell to $0.3M from $1.5M due to rNAPc2 trial closeout and 67% workforce reduction in July 2022.","Strategic review process ongoing with Ladenburg Thalmann; no defined timeline or guarantee of transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-033845","json":"https://secwatch.observer/filing/0000950170-23-033845.json","markdown":"https://secwatch.observer/filing/0000950170-23-033845.md","text":"https://secwatch.observer/filing/0000950170-23-033845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000095017023033845/0000950170-23-033845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000095017023033845/abio-20230721.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:17:23.850624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da7c7faf787eeed02ad4cf3a209387341aa520ea","claim":"Oruka Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $1.5 million, EPS $0.10 per basic and diluted share.","evidence_excerpt":"Net loss for the quarter ended June 30, 2023 was $1.5 million, or $0.10 per basic and diluted share, compared to $3.1 million, or $0.22 per basic and diluted share in the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017023033845/0000950170-23-033845-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"$1.5 million"},{"label":"EPS","value":"$0.10 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}